Neuromodulation: Technology at the Neural Interface Neuromodulation: Technology at the Neural Interface RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Deep Brain Stimulation of the Subgenual Cingulate Cortex for the Treatment of Chronic Low Back Pain
ConclusionsCLBP and depression share a common underlying brain network interconnected by the SCC. Current data and novel technology provide an optimal opportunity to develop clinically effective trials of SCC DBS for CLBP. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - April 19, 2021 Category: Biotechnology Authors: Alon Kashanian, Evangelia Tsolaki, Nader Pouratian, Ausaf A. Bari Tags: Review Article Source Type: research

Calendar of Events
(Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - April 19, 2021 Category: Biotechnology Tags: Professional Development Source Type: research

The Need for Digital Health Solutions in Deep Brain Stimulation for Parkinson's Disease in the Time of COVID ‐19 and Beyond
(Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - April 19, 2021 Category: Biotechnology Tags: CORRIGENDUM Source Type: research

Table of Contents
(Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - April 19, 2021 Category: Biotechnology Tags: Issue Information – Table of Contents Source Type: research

Editorial Board
(Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - April 19, 2021 Category: Biotechnology Tags: Issue Information – Editorial Board Source Type: research

Aims and Scope
(Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - April 19, 2021 Category: Biotechnology Tags: Issue Information – Aims and Scope Source Type: research

Cascade Programming for 10 kHz Spinal Cord Stimulation: A Single Center Case Series of 114 Patients With Neuropathic Back and Leg Pain
ConclusionCascade is an effective programming methodology that may have benefits over a single ‐bipole configuration for 10 kHz SCS, particularly during a trial of stimulation. Results from this study suggest it is a durable program for patients with neuropathic back and leg pain. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - April 19, 2021 Category: Biotechnology Authors: Adnan Al ‐Kaisy, Jonathan Royds, Omar Al‐Kaisy, Stefano Palmisani, David Pang, Tom Smith, Nick Padfield, Stephany Harris, Katie Markham, Samuel Wesley, Thomas Yearwood Tags: Clinical Research Source Type: research

Improved Psychosocial and Functional Outcomes and Reduced Opioid Usage Following Burst Spinal Cord Stimulation
ConclusionsOne ‐year outcomes after B‐SCS show improvements across all evaluated psychological measures with the largest impact observed on catastrophizing and depression (the affective component of pain processing). These pain‐related beliefs and behaviors, and not pain intensity, have been shown to put pat ients at greatest risk of a poor prognosis and quality of life. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - April 19, 2021 Category: Biotechnology Authors: Steven M. Falowski, Gregory A. Moore, Eric G. Cornidez, J. Kelby Hutcheson, Kenneth Candido, Isaac Pe ña, Bram Blomme, Robyn A. Capobianco Tags: Clinical Research Source Type: research

Novel Intermittent Dosing Burst Paradigm in Spinal Cord Stimulation
ConclusionsID burst SCS effectively relieved pain for six months. The largest group of subjects used IDB settings of 30  sec ON and 360 sec OFF. These findings present intriguing implications for the optimal “dose” of electricity in SCS and may offer many advantages such as optimizing the therapeutic window, extending battery life, reducing recharge burden and, potentially, mitigating therapy habituation or t olerance. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - April 19, 2021 Category: Biotechnology Authors: Timothy R. Deer, Denis G. Patterson, Javid Baksh, Jason E. Pope, Pankaj Mehta, Adil Raza, Filippo Agnesi, Krishnan V. Chakravarthy Tags: Clinical Research Source Type: research

The Long ‐Term Response to High‐Dose Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome After Conversion From Standard Spinal Cord Stimulation: An Effectiveness and Prediction Study
ConclusionsConverting patients with unsatisfactory responses from standard SCS to HD ‐SCS may be an effective strategy to obtain and maintain pain relief in a challenging subgroup of patients with FBSS refractory to standard SCS. The prediction models may guide clinicians in their decision making when considering conversion to HD‐SCS in patients with FBSS experiencing inadequate response to standard SCS. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - April 19, 2021 Category: Biotechnology Authors: Mats De Jaeger, Lisa Goudman, Raf Brouns, Ann De Smedt, Bengt Linderoth, Sam Eldabe, Discover consortium, Maarten Moens Tags: Clinical Research Source Type: research

Observations of Autonomic Variability Following Central Neuromodulation for Chronic Neuropathic Pain in Spinal Cord Injury
ConclusionsCentral modulation targeting the PNM produced autonomic changes in SCI  + NP persons but not AB persons. These findings suggest that AB persons exhibit intact CAN mechanisms capable of compensating for PNM aberrations or simply that SCI + NP persons exhibit altered PNM‐CAN machinery altogether. Our collective findings confirm the interconnectedness and malada ptive plasticity of PNM‐CAN machinery in SCI + NP persons and suggest that the PNM and CAN circuitry can be differentially modulated. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - April 19, 2021 Category: Biotechnology Authors: Jay Karri, Shengai Li, Yen ‐Ting Chen, Argyrios Stampas, Sheng Li Tags: Basic Research Source Type: research

Wireless Spinal Cord Stimulation Technology for the Treatment of Neuropathic Pain: A Single ‐Center Experience
ConclusionsMinimal invasive implantation of wireless SCS systems was feasible and safe. The device offered a broader range of stimulation paradigms compared to conventional SCS devices, an allowed for a prolonged testing phase and continuous adjustment of SCS programs. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - April 19, 2021 Category: Biotechnology Authors: Rezvan Ahmadi, Mohammad Mehdi Hajiabadi, Andreas Unterberg, Christiane Geist, Benito Campos Tags: Clinical Research Source Type: research

Cost ‐Effectiveness Model Shows Superiority of Wireless Spinal Cord Stimulation Implantation Without a Separate Trial
ConclusionsIn this model, compared with IPG SCS or with CMM, Wireless SCS is a superior strategy. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - April 19, 2021 Category: Biotechnology Authors: Richard B. North, Harish S. Parihar, Shawn D. Spencer, Arthur F. Spalding, Jane Shipley Tags: Clinical Research Source Type: research

Explantation Rates of High Frequency Spinal Cord Stimulation in Two Outpatient Clinics
ConclusionsRecently, high frequency SCS technology has been demonstrated as more effective in treatment of lower ‐ and leg‐pain, compared to conventional low frequency SCS, in a 12‐month randomized controlled trial (SENZA‐RCT). Longer term results have yet to be published. In this study, we found that the explantation rate was much higher than expected, based on the prior studies demonstrating its effi cacy. As the use of neuromodulation continues to grow, longitudinal data will be critical in understanding its long‐term effects on treated patients. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - April 19, 2021 Category: Biotechnology Authors: Victor C. Wang, Vickie Bounkousohn, Kara Fields, Clifford Bernstein, Richard M. Paicius, Christopher Gilligan Tags: Clinical Research Source Type: research

Using Lower Amplitudes to Maintain Effective High Dose Spinal Cord Stimulation Therapy (SCS Dosing Pilot Study)
ConclusionThe qualified study patients defined an implanted population reporting good pain relief and satisfaction using HD SCS therapy at baseline. The majority of these patients were able to maintain therapy satisfaction and pain relief (70% and 63.3%, respectively) with 20% perception threshold amplitude. Amplitudes below perception threshold could potentially maintain effective SCS therapy with HD stimulation in a subset of patients. (Source: Neuromodulation: Technology at the Neural Interface)
Source: Neuromodulation: Technology at the Neural Interface - April 19, 2021 Category: Biotechnology Authors: Amr O. El ‐Naggar, Christopher L. Reis, John A. Hatheway, Todd E. Schmidt, Tristan C. Pico, Mahendra R. Sanapati, Alaa Abd‐Elsayed, Amit S. Patel, Aaron Calodney, Lisa Johanek, Ye Tan, Sheryl McCammon Tags: Clinical Research Source Type: research